BMEYE was a Dutch medical device company founded in 2005 that developed ccNexfin™, a non-invasive hemodynamic monitoring technology using a finger cuff to provide continuous, real-time measurements of cardiac output, blood pressure, fluid responsiveness, and other parameters.[1][2][3] It served clinicians in surgical, intensive care, emergency room, and cardiology settings, addressing the need for beat-to-beat, patient-friendly monitoring to improve outcomes, reduce complications, and lower healthcare costs without invasive procedures.[1][3][4] The company achieved regulatory approvals in the US, Europe, and other regions, demonstrating early commercial traction before its acquisition by Edwards Lifesciences in 2012 for €32.5 million.[1][3]
BMEYE emerged in 2005 in the Netherlands as a specialist in cardiovascular monitoring technologies, focusing on non-invasive solutions for critically ill or surgical patients.[1][2] While specific founders are not detailed in available records, CEO Rob de Ree led the company during its growth phase, highlighting its "solid history of developing innovative hemodynamic monitoring solutions."[3][4] Early momentum came from the ccNexfin™ platform, which gained approvals for global sales and attracted investment from funds like LSP 3 (via EQT Life Sciences, entry 2006, exit 2014, though aligned with the 2012 acquisition).[5] A pivotal moment was the 2012 acquisition by Edwards Lifesciences, which integrated BMEYE's tech into broader portfolios and extended its reach.[1][3]
BMEYE rode the early 2010s trend toward non-invasive patient monitoring in medtech, driven by demands for cost-effective, real-time data amid rising healthcare expenses and focus on outcomes-based care.[3][4] Timing was ideal as hemodynamic monitoring gained evidence for reducing complications, aligning with shifts from reactive to proactive critical care.[3] Market forces like aging populations and surgical volume growth favored its tech, influencing the ecosystem by advancing finger-cuff innovations now standard in portfolios of giants like Edwards Lifesciences, which solidified leadership in monitoring post-acquisition.[1][3]
Post-2012 acquisition, BMEYE's technology has evolved within Edwards Lifesciences, likely integrated into platforms like EV1000 for expanded hospital use and novel developments.[3][4] Trends like AI-enhanced monitoring, wearable hemodynamics, and value-based care will shape its legacy, amplifying non-invasive tools amid precision medicine pushes. Its influence endures by enabling broader clinician access to vital data, tying back to BMEYE's founding vision of transforming patient care through accessible innovation.[1][3]
BMEYE has raised $9.0M in total across 1 funding round.
BMEYE's investors include Abingworth, Earlybird Venture Capital, EQT Life Sciences, SR One.
BMEYE has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series B in October 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2009 | $9.0M Series B | Abingworth, Earlybird Venture Capital, EQT Life Sciences, SR One |
